Newly diagnosed adolescents 8-17 years old with Type 1 diabetes
Placebo-Controlled Study to Evaluate Efficacy and Safety of Teplizumab, in Children and Adolescents, Newly Diagnosed Type 1 Diabetes
PRV-031
Study Length: 18 months
Target Age/Sex: 8 to 17 years old, Male and Female
Participants will receive at no cost: study product, study materials and study-specific procedures
Link: ClinicalTrials.gov